Agios Pharmaceuticals Inc (8AP.MU)
Munich - Munich Delayed price. Currency in EUR
Add to watchlist
At close: 08:11AM CEST
| Previous close | 32.20 |
| Open | 32.20 |
| Bid | 30.80 x N/A |
| Ask | 31.00 x N/A |
| Day's range | 32.20 - 32.20 |
| 52-week range | 19.10 - 32.20 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Earnings Beat: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Investors in Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO ) had a good week, as its shares rose 9.7% to close at US$34.54...
- Zacks
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.
- Insider Monkey
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call Transcript May 2, 2024 Agios Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to Agios’ First Quarter 2024 Conference Call. [Operator Instructions] Please be advised that […]
© 2024 Yahoo. All rights reserved.